Company Overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Recent Developments
- Dec 2025 Revenue of $4.48M (-51.3% YoY); net profit $-354.14M.
- Trailing 12 Months Year-on-year growth — revenue -89.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -28.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -28.33% |
| 1 Year: | -89.90% |
Stock Price Performance
| 1 Year: | +16.17% |
| 6 Months: | -26.80% |
| 3 Months: | +19.44% |
| 1 Month: | -2.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)49.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -28.3% CAGR over 5 years.
- Trading 34.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IVA Inventiva S.A. PHARMA | 4.67 | -2.14 | $1.10B | 0.00% | -77.20% | - | -28.33% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 12.18M | 17.48M | 9.20M | 4.48M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 69.04M | 120.14M | 103.19M | 137.37M |
| Operating Income | - | -56.86M | -102.67M | -93.99M | -132.88M |
| EBITDA | - | -51.89M | -102.04M | -166.53M | -317.33M |
| Interest Expense | - | 707.00K | 5.18M | 12.18M | 33.56M |
| Pretax Income | - | -54.29M | -109.82M | -183.90M | -354.11M |
| Tax Provision | - | -20.00K | 607.00K | 313.00K | 22.00K |
| Net Income | - | -54.27M | -110.43M | -184.21M | -354.14M |
| Diluted EPS | - | -1.31 | -2.43 | -3.08 | -1.90 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 116.00M | 69.56M | 118.97M | 249.51M |
| Current Assets | - | 106.38M | 48.19M | 111.51M | 244.47M |
| Cash & Equivalents | - | 86.74M | 26.92M | 96.56M | 99.31M |
| Inventory | - | 373.00K | 417.00K | 0 | 0 |
| Receivables | - | 0 | 3.81M | 531.00K | 2.02M |
| Total Liabilities | - | 70.53M | 101.59M | 225.61M | 278.03M |
| Current Liabilities | - | 30.70M | 50.16M | 120.73M | 77.38M |
| Long Term Debt | - | 25.43M | 27.91M | 46.33M | 26.82M |
| Total Debt | - | 34.52M | 37.49M | 54.33M | 59.86M |
| Total Equity | - | 45.48M | -32.03M | -106.65M | -28.52M |
| Shares Outstanding | - | 42.13M | 52.22M | 95.78M | 193.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -44.93M | -81.61M | -85.93M | -104.88M |
| Investing Cash Flow | - | 8.87M | -7.73M | 8.74M | -133.19M |
| Financing Cash Flow | - | 37.27M | 29.08M | 145.59M | 241.29M |
| Capital Expenditure | - | -561.00K | -540.00K | -333.00K | -247.00K |
| Free Cash Flow | - | -45.49M | -82.15M | -86.26M | -105.13M |
| Net Change in Cash | - | 1.21M | -60.26M | 68.41M | 3.22M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -466.8% | -587.4% | -1,021.8% | -2,964.2% |
| Net Margin % | - | -445.6% | -631.8% | -2,002.7% | -7,899.6% |
| ROE % | - | -119.3% | 344.7% | 172.7% | 1,241.6% |
| ROCE % | - | -66.7% | -529.1% | 5,328.2% | -77.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Caligan Partners, LP | 3.91% | 8.16M | $30.86M |
| 2 | Samsara BioCapital, LLC | 3.02% | 6.31M | $23.87M |
| 3 | Paradigm Biocapital Advisors LP | 1.91% | 4.00M | $15.12M |
| 4 | Andera Partners | 1.74% | 3.63M | $13.73M |
| 5 | Adar1 Capital Management, LLC | 1.73% | 3.61M | $13.63M |
| 6 | Millennium Management Llc | 1.68% | 3.51M | $13.28M |
| 7 | Nantahala Capital Management, LLC | 1.29% | 2.69M | $10.15M |
| 8 | Trails Edge Capital Partners, LP | 1.27% | 2.66M | $10.05M |
| 9 | Franklin Resources, Inc. | 1.26% | 2.64M | $9.99M |
| 10 | Squadron Capital Management LLC | 1.17% | 2.44M | $9.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IVA
Inventiva to Present Multiple Abstracts at Paris MASH 2026
Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize lanifibranor’s balanced pan-PPAR pha…
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference participation and tim…
Chris Benecchi Named Inventiva’s New Chief Operating Officer
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operat…
Inventiva Appoints Chris Benecchi as Chief Operating Officer
Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy fo…
Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio
Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio Carvolix is a listed French commercial- and clinical-stage medical technology companyDeveloping breakthrough AI-driven mini-rob…
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishe…
IVA — Frequently Asked Questions
What is the current share price of Inventiva S.A. (IVA)?
As of 2026-09-19 21:16 PDT, Inventiva S.A. (IVA) trades at $4.67 on NasdaqGM. Its 52-week range is $3.41 to $7.15.
What is the market capitalisation of IVA?
Inventiva S.A. (IVA) has a market capitalisation of $1.10B on NasdaqGM.
What is the P/E ratio of IVA?
IVA trades at a trailing price-to-earnings (P/E) ratio of -2.14. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -22.05.
Is IVA a good stock to buy?
This page provides a data-driven analysis of Inventiva S.A. (IVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.